Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience.
González-Calle V, Rodriguez-Otero P, Calasanz MJ, Guijarro M, Martínez-López J, Rosiñol L, Hernández MT, Teruel AI, Gironella M, Oriol A, de la Rubia J, González-Rodríguez AP, Bargay J, de Arriba F, Palomera L, González-Pérez MS, Sureda A, Ocio E, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Gutiérrez NC. González-Calle V, et al. Among authors: gironella m. Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39665068 Free PMC article.
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, López-Martínez A, Altés A, Ruíz MÁ, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernández R, Bladé Creixenti J, Lahuerta JJ, San-Miguel J, Hernández MT. Lakhwani S, et al. Among authors: gironella m. Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06031-0. Online ahead of print. Ann Hematol. 2024. PMID: 39438321
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Popat R, Augustson B, Gironella M, Lee C, Cannell P, Patel N, Kasinathan RS, Rogers R, Shaikh M, Curry A, Carreño F, Roy-Ghanta S, Opalinska J, Quach H. Popat R, et al. Among authors: gironella m. Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y. Blood Cancer J. 2024. PMID: 39433730 Free PMC article.
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. J Clin Oncol. 2024 Oct 1:JCO2400635. doi: 10.1200/JCO.24.00635. Online ahead of print. J Clin Oncol. 2024. PMID: 39353166
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.
Alegre A, Gironella M, Escalante F, Bergua JM, Martínez-Chamorro C, López A, González E, Bárez A, Somolinos N, Persona EP, Cabrera AS, Soler A, Rodríguez BI, López JM, González Y, Giménez VC, Sampol A, Muñoz C, Vilanova D, Durán M, Fernández de Larrea C; Spanish Myeloma Group (GEM_PETHEMA). Alegre A, et al. Among authors: gironella m. Hemasphere. 2024 Jul 4;8(7):e81. doi: 10.1002/hem3.81. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38974896 Free PMC article.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
Variance sum rule for entropy production.
Di Terlizzi I, Gironella M, Herraez-Aguilar D, Betz T, Monroy F, Baiesi M, Ritort F. Di Terlizzi I, et al. Among authors: gironella m. Science. 2024 Mar;383(6686):971-976. doi: 10.1126/science.adh1823. Epub 2024 Feb 29. Science. 2024. PMID: 38422150
128 results